GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
CompareExenatide vs Orforglipron
Ingredient comparison

Exenatide vs Orforglipron

Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.

Every cash quote was checked on or after Sep 26, 2026.Data feeds · Oct 3, 2026 UTC
OverviewDirect evidenceCash pricesTrial resultsChange comparison
Exenatide vs Orforglipron: overview
CompareExenatideOrforglipron
Brands

Exenatide

Byetta (discontinued), Bydureon BCise (discontinued), Generic exenatide

GLP-1

Orforglipron

Foundayo

Small-molecule GLP-1

Route & frequency

Exenatide

Subcutaneous injection

Twice daily (Byetta); once weekly (Bydureon BCise)

What was tested together

Direct comparative evidence

No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.

Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Exenatide vs Orforglipron: sourced cash quotes
CompareExenatideOrforglipron
Advertised entry price

Exenatide

~$447 per pen

Generic exenatide (Amneal)

GoodRx

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Third-party reported price

Supply period unverified; excluded from cost ranking.

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Exenatide vs Orforglipron: individual trial outcomes
CompareExenatideOrforglipron
Weight change

Exenatide

≈−3.6% (-3.7 kg (~3.6%) at 30 wks · DURATION-1 · 2 mg weekly (Bydureon))

-3.7 kg (~3.6%) at 30 wks

DURATION-1

2 mg weekly (Bydureon)

Check the product label

Approved uses & full records

Exenatide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

378 registered ingredient studies. Count checked Oct 3, 2026. Research activity, not a measure of evidence quality.

Open full record

Orforglipron

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

53 registered ingredient studies. Count checked Oct 3, 2026. Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Which costs less: Exenatide or Orforglipron?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Other comparisons
Semaglutide vs ExenatideSemaglutide vs OrforglipronTirzepatide vs ExenatideTirzepatide vs OrforglipronLiraglutide vs ExenatideLiraglutide vs Orforglipron

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier

Orforglipron

Oral tablet (any time of day, no food or water restriction)

Once daily

FDA shortage report

Exenatide

National reporting does not confirm stock at your pharmacy.

Coverage & source records

Orforglipron

National reporting does not confirm stock at your pharmacy.

Coverage & source records
Checked Sep 30, 2026
Price conditions

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

AstraZeneca discontinued both branded products in 2024 (Byetta and Bydureon BCise), and Byetta's approval was withdrawn in 2025. Only generic exenatide (Amneal) remains; residual branded stock may still appear at the pharmacy.

Orforglipron

from $149/mo

Foundayo (LillyDirect self-pay)

LillyDirect (Eli Lilly)

self-pay cash, lowest dose; ~$25/mo with commercial coverage

30-day supply

$149 per 30 days at this quoted rate

Checked Sep 30, 2026

Price conditions

self-pay cash, lowest dose; ~$25/mo with commercial coverage

The first oral small-molecule GLP-1 pill for weight loss; FDA-approved April 2026. LillyDirect self-pay ladder: $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg), $299 (14.5 and 17.2 mg with a 45-day refill, else $349); the 2.5 mg and 5.5 mg doses are temporarily $149 and $199 through Dec 31, 2026.

30-day supply

At the named trial dose

Exenatide

No sourced quote tracked for this price basis.

Orforglipron

$299/mo

Foundayo (LillyDirect self-pay)

At 17.2 mg

LillyDirect (Eli Lilly)

Published price at 17.2 mg

30-day supply

$299 per 30 days at this quoted rate

Checked Sep 30, 2026

Price conditions

Published price at 17.2 mg

The first oral small-molecule GLP-1 pill for weight loss; FDA-approved April 2026. LillyDirect self-pay ladder: $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg), $299 (14.5 and 17.2 mg with a 45-day refill, else $349); the 2.5 mg and 5.5 mg doses are temporarily $149 and $199 through Dec 31, 2026.

Self-Pay Journey price for 14.5 mg and 17.2 mg with a refill within 45 days; regular price $349. Eligibility, additional taxes and fees may apply.

30-day supply

Explore product prices

Exenatide

All Exenatide offers

Orforglipron

All Orforglipron offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Approximation from kilograms; see trial methods

Study context

The oldest GLP-1; a diabetes trial with a modest weight effect.

Orforglipron

−11.2% (-11.2% at 72 wks · ATTAIN-1 · 17.2 mg daily (Foundayo; 36 mg capsule-equivalent in ATTAIN-1))

-11.2% at 72 wks

ATTAIN-1

17.2 mg daily (Foundayo; 36 mg capsule-equivalent in ATTAIN-1)

Accounts for treatment discontinuation

Study context

The first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%.

HbA1c change (percentage points)

Exenatide

−1.9 pp (-1.9% at 30 wks · DURATION-1 · HbA1c change in percentage points)

-1.9 percentage points at 30 wks

DURATION-1
Study context

The oldest GLP-1; a diabetes trial with a modest weight effect.

Orforglipron

−1.5 pp (-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1) · ACHIEVE-1 · HbA1c change in percentage points)

-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1)

ACHIEVE-1
Study context

The first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%.

Adverse events

Exenatide

Stopped treatment for adverse events

3.9% (3.9% discontinued for adverse reactions · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Reported nausea

8.2% (Nausea in the drug arm · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Bydureon BCise FDA label (2 mg, type 2 diabetes)

from the FDA label adverse-reactions table (DURATION-1 does not cleanly report AE discontinuation); a diabetes population

Orforglipron

Stopped treatment for adverse events

10.3% (10.3% vs 2.7% placebo (36 mg) · ATTAIN-1 (36 mg, 72 wks, obesity))

Reported nausea

33.7% (Nausea in the drug arm · ATTAIN-1 (36 mg, 72 wks, obesity))

ATTAIN-1 (36 mg, 72 wks, obesity)